From: In silico pathway analysis based on chromosomal instability in breast cancer patients
S.No | Patient group and controls | Mean (%) TAM | Mean (%) MSA | Mean (%) MNA | Mean (%) M(SA + NA)# | Mean MAA (%) |
---|---|---|---|---|---|---|
1 | Stage I cases (n = 20) Controls (n = 20) p-value | 20.6 ± 7.6 10.3 ± 3.0  < 0.0001 | 9.3 ± 5.8 4.7 ± 3.1 0.0034 | 9.2 ± 5.0 4.5 ± 3.2 0.0011 | 3.0 ± 2.3 1.2 ± 1.1 0.0031 | 28.6 ± 13.5 30.2 ± 11.8 0.069 |
2 | Stage II cases (n = 74)* Controls (n = 74) p-value | 12.0 ± 9.2 12.9 ± 5.0 0.4609 | 13.1 ± 9.2 4.7 ± 3.2  < 0.0001 | 9.4 ± 6.2 6.3 ± 3.4 0.0002 | 2.2 ± 1.5 2.0 ± 1.4 0.4031 | 28.3 ± 15.0 29.6 ± 15.0 0.5989 |
3 | Stage III cases(n = 37) Control (n = 37) p-value | 21.7 ± 12.1 11.9 ± 4.1  < 0.0001 | 10.6 ± 7.9 4.1 ± 2.8 0.0015 | 9.4 ± 7.5 6.3 ± 3.4 0.0250 | 3.5 ± 2.8 1.5 ± 1.2 0.0002 | 26.0 ± 13.2 18.9 ± 17.9 0.0561 |
4 | Stage IV cases (n = 14) Controls (n = 14) p-value | 22.2 ± 9.7 13.8 ± 5.1 0.0081 | 10.9 ± 7.2 5.1 ± 3.5 0.0117 | 10.2 ± 9.2 6.8 ± 3.9 0.2142 | 2.1 ± 1.0 1.9 ± 1.8 0.7192 | 31.6 ± 19.3 26.1 ± 18.5 0.4484 |
5 | Indeterminate stage cases (n = 5) Controls (n = 5) p-value | 16.7 ± 2.4 13.0 ± 5.5 0.2053 | 4.7 ± 3.3 3.7 ± 2.2 0.5883 | 11.5 ± 3.3 7.7 ± 4.8 0.1828 | 1.0 ± 0.0 1.6 ± 1.5 0.3972 | 24.6 ± 8.1 26.0 ± 14.0 0.8514 |